Influence of plasma T790M mutation on clinical decision after 1st generation EGFR-TKI resistance in a Real-world study

被引：0
|
作者：
Zhang, S. [1 ]
Zhu, L. [2 ]
Xia, B. [2 ]
Chen, X. [3 ]
Ma, S. [2 ]
机构：
[1] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Hangzhou Translat Med Res Ctr, Hangzhou, Zhejiang, Peoples R China
[2] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Radiat Oncol, Hangzhou, Zhejiang, Peoples R China
[3] Nanjing Med Univ, Hangzhou Peoples Hosp 1, Med Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1332P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Detection of plasma T790M mutation after the first generation EGFR-TKI resistance of non-small cell lung cancer in the real world
    Li, Haiyan
    Wang, Jinwei
    Zhang, Guojing
    Li, Yuping
    Lin, Ling
    Yang, Haihua
    Zhou, Jingjing
    Zhang, Lingna
    Lv, Dongqing
    JOURNAL OF THORACIC DISEASE, 2020, 12 (03) : 550 - 557
  • [2] Detection of Plasma T790M Mutation After the First Generation EGFR-TKI Resistance of Non-Small Cell Lung Cancer in the Real World
    Li, H.
    Lv, D.
    Xu, H.
    Ye, M.
    Wu, X.
    Kong, F.
    Yang, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S595 - S596
  • [3] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
    Luo, Yung-Hung
    Liu, Han
    Wampfler, Jason A.
    Tazelaar, Henry D.
    Li, Yalun
    Peikert, Tobias
    Liu, Dan
    Leventakos, Konstantinos
    Chen, Yuh-Min
    Yang, Yanan
    Chiou, Shih-Hwa
    Yang, Ping
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) : 2099 - 2114
  • [4] Real-world efficacy of osimertinib in previously EGFR-TKI treated NSCLC patients without identification of T790M mutation
    Yung-Hung Luo
    Han Liu
    Jason A. Wampfler
    Henry D. Tazelaar
    Yalun Li
    Tobias Peikert
    Dan Liu
    Konstantinos Leventakos
    Yuh-Min Chen
    Yanan Yang
    Shih-Hwa Chiou
    Ping Yang
    Journal of Cancer Research and Clinical Oncology, 2022, 148 : 2099 - 2114
  • [5] T790M MUTATION ASSOCIATED WITH BETTER EFFICACY OF CONTINUOUS EGFR-TKI TREATMENT IN ADVANCED NSCLC PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Ren, Shengxiang
    Li, Wei
    Li, Aiwu
    Chen, Xiaoxia
    Gao, Guanghui
    He, Yayi
    Li, Xuefei
    Zhou, Caicun
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1084 - S1084
  • [6] Real-world data of EGFR minor mutated NSCLC treated with EGFR-TKI: Comparative analysis including compound mutation and de novo T790M mutation
    Tanaka, K.
    Inui, N.
    Asada, K.
    Abe, T.
    Hataji, O.
    Hayai, S.
    Ito, K.
    Imaizumi, K.
    Kimura, T.
    Kubo, A.
    Kunii, E.
    Murotani, K.
    Okuno, M.
    Oya, Y.
    Shindoh, J.
    Taniguchi, H.
    Tsuda, T.
    Yamaguchi, T.
    Hida, T.
    Suda, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [7] De Novo Emergence of Isolated CNS T790M Mutation as a Mechanism of Resistance to First Generation EGFR-TKI Erlotinib
    Al Rabadi, L.
    Tolba, K.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1048 - S1048
  • [8] Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
    D. Zheng
    X. Ye
    M. Z. Zhang
    Y. Sun
    J. Y. Wang
    J. Ni
    H. P. Zhang
    L. Zhang
    J. Luo
    J. Zhang
    L. Tang
    B. Su
    G. Chen
    G. Zhu
    Y. Gu
    J. F. Xu
    Scientific Reports, 6
  • [9] Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance
    Zheng, D.
    Ye, X.
    Zhang, M. Z.
    Sun, Y.
    Wang, J. Y.
    Ni, J.
    Zhang, H. P.
    Zhang, L.
    Luo, J.
    Zhang, J.
    Tang, L.
    Su, B.
    Chen, G.
    Zhu, G.
    Gu, Y.
    Xu, J. F.
    SCIENTIFIC REPORTS, 2016, 6
  • [10] Detection of the T790M Mutation of EGFR in Plasma of Advanced NSCLC Patients with Acquired Resistance to EGFR-TKI (WJOG8014LTR)
    Azuma, Koichi
    Takahama, Takayuki
    Sakai, Kazuko
    Takeda, Masayuki
    Hida, Toyoaki
    Hirabayashi, Masataka
    Oguri, Tetsuya
    Tanaka, Hiroshi
    Ebi, Noriyuki
    Sawa, Toshiyuki
    Bessho, Akihiro
    Tachihara, Motoko
    Akamatsu, Hiroaki
    Bandoh, Shuji
    Himeji, Daisuke
    Ohira, Tatsuo
    Shimokawa, Mototsugu
    Yamamoto, Nobuyuki
    Nakanishi, Yoichi
    Nakagawa, Kazuhiko
    Nishio, Kazuto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S389 - S390
12345